Shire finally files ADHD drug Venvanse in EU
This article was originally published in Scrip
Executive Summary
An EU approval for Shire's attention-deficit hyperactivity disorder (ADHD) drug Venvanse (lisdexamfetamine dimesylate) is edging closer after the UK's medicines regulator, the MHRA agreed to act the reference member state under the decentralised procedure. The drug was first approved in the US back in February 2007 under the name Vyvanse.